Salubris Biotherapeutics Inc. announced that it will receive CNY 63.90 million in funding from returning investor Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) on May 19, 2018. The transaction has been approved at the 12th session of the 4th directorate of the investor. The company reported total assets of CNY 34,981,400, total common equity of CNY CNY 31,862,800, and net income of -–CNY 16,745,800 for the year ended 2017.